Creoptix

Creoptix

Creoptix

Sensitivity and flexibility in drug discovery beyond Surface Plasmon Resonance. Industry leading sensitivity, fast kinetics, the most robust microfluidics
Type
B2b
Founded
2009
Raised
$3.3M
Follow us
Alexa global traffic share
Latest funding
$3,270,120
Venture capital (Series A) - 2013
Team Size
1–10
Employees
PrivateEquityWire

Creoptix backs scientist developing antibody test